MaxCyteMXCT +3.91%64 Cyclically Adjusted PB Ratio is 0.97 as of Jul. 13, 2026, which is 80% below its 10-year median of 4.80. GuruFocus rates MXCT with a GF Score™ of 64/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 524 Medical Devices & Instruments companies, MaxCyte ranks better than 69.47% on this metric.
As of today (2026-07-13), MaxCyte's current share price is $1.325. MaxCyte's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 was $1.37. MaxCyte's Cyclically Adjusted PB Ratio for today is 0.97.
The historical rank and industry rank for MaxCyte's Cyclically Adjusted PB Ratio or its related term are showing as below:
MXCT'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.5 Med: 4.8 Max: 16.97
Current: 0.97
During the past 13 years, MaxCyte's highest Cyclically Adjusted PB Ratio was 16.97. The lowest was 0.50. And the median was 4.80.
MXCT's Cyclically Adjusted PB Ratio is ranked better than 69.47% of 524
companies
in the Medical Devices & Instruments industry
Industry Median: 1.8
vs MXCT: 0.97
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
MaxCyte's adjusted book value per share data of for the fiscal year that ended in Dec25 was $1.606. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.37 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
MaxCyte (NAS:MXCT) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
MaxCyte Cyclically Adjusted PB Ratio Related Terms
MaxCyte Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for MaxCyte's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MXCT vs RCEL, HYPR, CVRX: Cyclically Adjusted PB Ratio Comparison
For the Medical Devices subindustry, MaxCyte's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where MaxCyte's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
MaxCyte's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.97 mean?
MaxCyte (MXCT) has a Cyclically Adjusted PB Ratio of 0.97 as of Jul. 13, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on MaxCyte and its competitors. This is 80% below median its historical median of 4.80. Over the past decade, MaxCyte's Cyclically Adjusted PB Ratio has ranged from 0.50 to 16.97. According to the industry distribution chart, MaxCyte ranks #160 out of 524 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is MaxCyte's Cyclically Adjusted PB Ratio too high?
MaxCyte's current Cyclically Adjusted PB Ratio of 0.97 is 80% below median its 10-year median of 4.80. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 16.97. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.80. MaxCyte's value of 0.97 is 46.1% below this industry median. Based on the distribution chart, MaxCyte ranks #160 out of 524 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MaxCyte has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Cyclically Adjusted PB Ratio compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #160 out of 524 companies for Cyclically Adjusted PB Ratio. This puts MaxCyte in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.80. MaxCyte's value of 0.97 is 46.1% below this benchmark. Historically, MaxCyte's own Cyclically Adjusted PB Ratio has ranged from 0.50 to 16.97 over the past decade. While the company's 10-year median is 4.80 vs. the industry median of 1.80, MaxCyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.80, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Cyclically Adjusted PB Ratio of 0.97 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Cyclically Adjusted PB Ratio is 0.97, which is 80% below median its own 10-year median of 4.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.33 — trading 48.4% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.97, which is 80% below median its 10-year median of 4.80 and 46.1% below the Medical Devices & Instruments industry median of 1.80. MaxCyte's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For MaxCyte (MXCT), the current Cyclically Adjusted PB Ratio is 0.97 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.33 is trading 48.4% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Cyclically Adjusted PB Ratio: 0.97 (80% below median its 10-year median of 4.80)
GF Value™: $2.57 vs. price of $1.33 (48.4% below fair value)
Industry Position: 46.1% below the Medical Devices & Instruments median (#160 of 524)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
64GF Score
Get the complete analysis for MXCT
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
